<p>C57BL/6 mice were immunized by the vaginal or nasal route with OVA Alexa Fluor 647-conjugate (25 µg/mouse) and CpG ODN (20 µg/mouse). Groups of animals were sacrificed 0, 12, 24 and 72 hours after mucosal immunization and iliac lymph nodes (considered draining after vaginal and distal after nasal immunization respectively), cervical lymph nodes (distal after vaginal and draining after nasal immunization respectively) and spleen were collected. DCs positive for fluorescent OVA were analysed by flow cytometry. Shown is the percentage of OVA-Alexa Fluor 647 positive cells among total CD11c<sup>+</sup> MHC class II<sup>+</sup> cells.</p
<p>Each mouse group was nasally immunized three times at weekly intervals with OVA plus Ad-FL. (A) S...
(A) Experimental design and gating strategy: To assess antigen uptake by DCs and to track the DCs, C...
<p>The clonal expansion of adoptively transferred CD4<sup>+</sup> T cells following vaginal or nasal...
<p>C57BL/6 mice were immunized by the nasal route with OVA-Alexa fluor 647 conjugate (25 µg/mouse) a...
<p>CFSE-labelled OT-II CD4<sup>+</sup> T cells were transferred into recipient C57BL/6J mice. Twenty...
<p>CD4+ T cells, isolated from OT-II mice, were labeled with CFSE and adoptively transferred into re...
<p>(A and C) CD11c-DTR, CD11c-DTR/C57BL/6, CD11c-DTR/CCR5<sup>−/−</sup> and CD11c-DTR/CCR6<sup>−/−</...
a<p>Mice were nasally immunized weekly for three consecutive weeks with OVA plus Ad-FL.</p><p>One we...
<p>Mice were intranasally immunized with OVA either alone (open column) or with 500 µg of PMB (close...
Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccinatio...
<p>OVA-specific proliferation of CD4<sup>+</sup> T cells was assessed 57 hours following immunizatio...
Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccinatio...
<p>Mice were intranasally immunized with OVA plus 500 µg of PMB 3 times at weekly intervals. One gro...
<p>(A) C57BL/6 mice were injected with CD45.1<sup>+</sup> WT DC or CD45.1<sup>+</sup> WT DC loaded w...
<p>(<b>A</b>) BM-DC were incubated with indicated concentrations of OVA or OVA-Cl for 2 h at 37°C. W...
<p>Each mouse group was nasally immunized three times at weekly intervals with OVA plus Ad-FL. (A) S...
(A) Experimental design and gating strategy: To assess antigen uptake by DCs and to track the DCs, C...
<p>The clonal expansion of adoptively transferred CD4<sup>+</sup> T cells following vaginal or nasal...
<p>C57BL/6 mice were immunized by the nasal route with OVA-Alexa fluor 647 conjugate (25 µg/mouse) a...
<p>CFSE-labelled OT-II CD4<sup>+</sup> T cells were transferred into recipient C57BL/6J mice. Twenty...
<p>CD4+ T cells, isolated from OT-II mice, were labeled with CFSE and adoptively transferred into re...
<p>(A and C) CD11c-DTR, CD11c-DTR/C57BL/6, CD11c-DTR/CCR5<sup>−/−</sup> and CD11c-DTR/CCR6<sup>−/−</...
a<p>Mice were nasally immunized weekly for three consecutive weeks with OVA plus Ad-FL.</p><p>One we...
<p>Mice were intranasally immunized with OVA either alone (open column) or with 500 µg of PMB (close...
Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccinatio...
<p>OVA-specific proliferation of CD4<sup>+</sup> T cells was assessed 57 hours following immunizatio...
Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccinatio...
<p>Mice were intranasally immunized with OVA plus 500 µg of PMB 3 times at weekly intervals. One gro...
<p>(A) C57BL/6 mice were injected with CD45.1<sup>+</sup> WT DC or CD45.1<sup>+</sup> WT DC loaded w...
<p>(<b>A</b>) BM-DC were incubated with indicated concentrations of OVA or OVA-Cl for 2 h at 37°C. W...
<p>Each mouse group was nasally immunized three times at weekly intervals with OVA plus Ad-FL. (A) S...
(A) Experimental design and gating strategy: To assess antigen uptake by DCs and to track the DCs, C...
<p>The clonal expansion of adoptively transferred CD4<sup>+</sup> T cells following vaginal or nasal...